EyePoint Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de EyePoint Pharmaceuticals han disminuido a una tasa media anual de -16.4%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 1.2% anualmente. Los ingresos han ido creciendo a una tasa media de 14.8% al año.
Información clave
-16.4%
Tasa de crecimiento de los beneficios
20.7%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals | 6.0% |
Tasa de crecimiento de los ingresos | 14.8% |
Rentabilidad financiera | -47.3% |
Margen neto | -226.6% |
Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
Nov 14Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
Oct 29EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06Desglose de ingresos y gastos
Cómo gana y gasta dinero EyePoint Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Sep 24 | 46 | -104 | 51 | 0 |
30 Jun 24 | 50 | -87 | 49 | 21 |
31 Mar 24 | 50 | -79 | 50 | 0 |
31 Dec 23 | 46 | -71 | 51 | 0 |
30 Sep 23 | 43 | -100 | 55 | 0 |
30 Jun 23 | 37 | -106 | 59 | 27 |
31 Mar 23 | 40 | -102 | 60 | 0 |
31 Dec 22 | 41 | -102 | 60 | 0 |
30 Sep 22 | 42 | -78 | 64 | 0 |
30 Jun 22 | 41 | -77 | 62 | 0 |
31 Mar 22 | 39 | -67 | 58 | 0 |
31 Dec 21 | 37 | -58 | 54 | 0 |
30 Sep 21 | 33 | -54 | 48 | 0 |
30 Jun 21 | 39 | -42 | 45 | 0 |
31 Mar 21 | 34 | -44 | 44 | 0 |
31 Dec 20 | 34 | -45 | 46 | 0 |
30 Sep 20 | 36 | -40 | 46 | 0 |
30 Jun 20 | 23 | -52 | 47 | 0 |
31 Mar 20 | 26 | -51 | 48 | 0 |
31 Dec 19 | 20 | -57 | 48 | 0 |
30 Sep 19 | 14 | -58 | 45 | 0 |
30 Jun 19 | 12 | -75 | 41 | 0 |
31 Mar 19 | 6 | -98 | 35 | 0 |
31 Dec 18 | 5 | -86 | 25 | 0 |
30 Sep 18 | 3 | -80 | 18 | 0 |
30 Jun 18 | 3 | -53 | 13 | 0 |
31 Mar 18 | 3 | -25 | 10 | 0 |
31 Dec 17 | 3 | -23 | 10 | 0 |
30 Sep 17 | 8 | -17 | 9 | 0 |
30 Jun 17 | 8 | -18 | 11 | 0 |
31 Mar 17 | 7 | -19 | 10 | 0 |
31 Dec 16 | 7 | -19 | 10 | 0 |
30 Sep 16 | 1 | -24 | 10 | 0 |
30 Jun 16 | 2 | -22 | 9 | 0 |
31 Mar 16 | 2 | -20 | 9 | 0 |
31 Dec 15 | 2 | -20 | 8 | 0 |
30 Sep 15 | 2 | -19 | 8 | 0 |
30 Jun 15 | 27 | 6 | 8 | 0 |
31 Mar 15 | 26 | 8 | 8 | 0 |
31 Dec 14 | 28 | 10 | 8 | 0 |
30 Sep 14 | 28 | 11 | 7 | 0 |
30 Jun 14 | 3 | -13 | 7 | 0 |
31 Mar 14 | 4 | -13 | 8 | 0 |
31 Dec 13 | 2 | -14 | 7 | 0 |
Ingresos de calidad: EYPT actualmente no es rentable.
Margen de beneficios creciente: EYPT actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: EYPT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 16.4% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de EYPT en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: EYPT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (54.6%).
Rentabilidad financiera
Alta ROE: EYPT tiene una rentabilidad financiera negativa (-47.35%), ya que actualmente no es rentable.